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ABSTRACT
Ora l gancic lo vi r is effective in pre ve n t in g cytomega lovirus (CMV) d isease in HI V- infec ted patients despite a
hioavai lah ility of only 6-9%. To determine safety, pharmacokinetics, and the in fluence of acute gast ro in tes ti nal
graft-vs .-host disease (GI -GVHO) on th e bioavailah iliry and antiviral effect of ora) g:lIIciclo vir after marrow trans-
plantation, CMV seropo sitive patients received oral gancicl ll\; r (1000 mg 3 times per day) from day 35 (± 7 days)
until day 100 after trans plantation. Single-dose (intravenous an d oral) and steady -state oral phnrm nco kiner ic p ro files
an d weekly troug h levels were pe rfo rm ed. Twenty-one patient s received oral ganciclovir (seven wi th G I-GVHO, 14
wit hout); 17 had steady -state pharmaco kin e tic p ro files an d seven had single-dose pro fil es. T he abso lute hioavai lahi l-
ity was similar in patient s wit h or wi thout acute G I-GVI IO (7.2 vs. 6.9 %). At steady sta te, th e ex tent and rate of
ahs0'lltinn nf oral ganciclm; r were co m parable in these same patient suhgro ups (area unde r t he curve IAUCI = l .l .5
an d 10.2 mg-hou rs/ L, respectively; t im e to peak se ru m gn nciclovir co ncen tratio ns = 5.5 an d 3.8 hou rs, re spectively).
Breakth rough CMV nntigeucm ia, vire mia, or pl asma pol ym e ra se chai n reaction positivity occurred in e ight of 2 1
(38 %) patients (fo ur of seven with GVH D and four of 14 wi thout). D ru g d iscont inuati on becau se of G I adverse
e ffects was re q uired in six o f 2 1 (29%) pat ients. Neutrope nia occu r red in tw o o f 15 ( I .l%) patient s who had received
oral gunciclovir for more th an J() days. In co nclusi o n, th e hioavuilahil iry o f oral ga nc iclovir seems sim ilar to tha t
reported in n thcr se tti ngs. T he presen ce of ac ute GVI ID of th e G I tra ct did not appear' to adverse ly affect ahsorp -
t ion of oral gn nc ic lov ir, T he usc o f o ral ga nc ic lovir was limit ed hy the (Iresen ce o f G I intolerance in th e ea rly post -
t ranspl ant pe riod . T he eflicuc y of om) ga nc iclovir in preventing C ,\lV infection in marro w transp lan t recipie nts is
he ing assessed in a se para te rnndomized co ntrolled tria l.
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INTRODUCTION
Cyto ll1 cgalovirus (C\1V) is an opport unistic infectio n in
Illarn ,\\. tr auspl un r rec ip ients [ I I. ln t ra vcno us (i.v.) gnnc i-
·n);.. IllIdv ;" 1/s .I'lIpp",.,..d bv Rod", Gtob«! f)I~ 'd"PlI/t'JI l '/Jul by 11.>" National
1/I,-,illll"I oj'II.',illI.> (C 'I I so:» /i\l,fl . ,lIId R..'I,lt.] C·, W!06 '1.7..'" Z.f), '11'1'
SPO/lI'W... I.>I/d 110 roll' ill 11.>,· colirctio» O( dlllil 0 " its intrrprrtation and '1II1I/l'Iis,
1',WI'pl j iJl' 11"' 1,!J'II'II/II(ol-illl'li( analvsis, irbirb 11',IJ I...,./;)/'II/,·d 1,\· Rod)I' G/obll/D . ,11'dof>/IIt'JIl ,
c lovi r, ;\ syn the tic nu cleosid e analog, has been used success-
fully fo r the prevention o f C \ IV disease a[ter allogen eic ma r-
row transplan ta t io n 12- 71 . l lo wc vcr, problems assoc ia te d
with th e i.v, rout e o f admi nistra tion, such as cos t, inco nve-
nicnce, and carhc tc r- rc l.ued co m plicatio ns (c.g., bacte remi a),
co upled with th e need fo r o ngoi ng C \,IV prophylaxis for up
to 120 days ufrc r marrow tr an spl ant at ion 1.\,41. (;1\'01' th c usc
o f an ora l dosage lonnulurion . Recent approva ls in th e Un it -
cd Suu es o f oral ~a nc idovi r till' prophylaxis o f C \ l V diseuse
in 11IV- in fcctcd pat ien ts IHI and in so lid orga n transpl ant
rcc ip ie u ts 11)1 offer t h e po ssih ilit y of a more pra ct ical
approach to the prevention of CMV disease following allo-
geneic marrow transplantation.
Patients who develop acute graft-vs.-host disease
(GVHD) after marrow transplantation are at particularly
high risk for CMV disease [10,11], and, therefore, adequate
antiviral prophylaxis is critical for these patients. However,
acute GVHD of the gastrointestinal tract (GI-GVHD), a
common feature of transplantation, can influence the
absorption of several drugs, including cyclosporine [12] and
thalidomide [13]. Because the estimated oral bioavailability
of ganciclovir is low, ranging from 6 to 9% in HN-positive
individuals [14,15], any possible influence of acute GI-
GVHD on the drug's GI absorption could have important
therapeutic repercussions.
The present study was designed to establish the oral
bioavailability of ganciclovir in the absence and presence of
acute GI-GVHD in CMV-seropositive allogeneic marrow
transplant recipients, and to assess the antiviral activity and
potential toxicity of oral ganciclovir in this setting.
MATERIALS AND METHODS
Study design
This was a three-center, open-label uncontrolled study
of oral ganciclovir for the prevention of CMV disease. Oral
ganciclovir (1000 mg) was administered 3 times per day from
study entry until day 100 after transplantation. In a subset of
patients, oral and i.v, single-dose pharmacokinetic studies
were performed on 2 consecutive days before starting oral
treatment 3 times per day. In these single-dose studies,
patients randomly were assigned to receive either the oral or
i.v, route of therapy on day 1, with the alternate route given
on day 2. At study entry, patients were categorized according
to the absence or presence of acute GI-GVHD. After the
required number of patients without GI-GVHD was
achieved, only patients with GI-GVHD were enrolled.
Definitions
GI-GVHD was defined as (1) biopsy-proven GVHD of
the GI tract plus diarrhea (>300 mL/day), (2) biopsy-
proven GVIID of the GI tract and nausea, (3) documented
acute GVHD of the liver (stage II, total bilirubin>3 mg/dL
or biopsy-proven) plus diarrhea (>500 mLiday) with no
other explanation, or (4) biopsy-proven acute GVIID of the
skin plus diarrhea (>500 mUday) with no other explanation
[16J. Acute GVHD was treated with systemic cortico-
steroids at a dose of 2 mg/kg/day for 7-10 days followed by
dose reduction [17]. CMV infection was defined as (1) CMV
viremia by culture, (2) CMV antigenemia at any quantitative
level, or (3) plasma polymerase chain reaction (PCR) posi-
tivity. CMV disease was defined as CMV identified in the
tissue or bronchoalveolar lavage (BAL) by either culture or
immunohistology in the presence of compatible clinical
symptoms [3,7]. Neutropenia (marrow toxicity) was defined
as an absolute neutrophil count (ANC) of <750/mm3 for 2
or more consecutive days.
Patients
Study participants were>18 years old and the recipients
of allogeneic marrow or peripheral blood stem cell trans-
plants who were seropositive for CMV. Patients were
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required to have negative CMV antigenemia and virus culture
results in their blood (Fred Hutchinson Cancer Research
Center [FHCRq and the Veterans Affairs Medical Center
[VAMC]) or negative virus culture results in their blood and
BAL (City of Hope National Medical Center [COH]) during
the first 35 days after transplantation, to be able to take oral
medication, and to have an ANC of >750/mm3 for 2 consec-
utive days. Patients with or without acute GI-GVHD were
eligible to enter the study. Exclusion criteria included renal
impairment (calculated creatinine clearance [CL CR] <:70
mLiminute), severe hepatic dysfunction (total bilirubin >10
mg/dL), a history of hypersensitivity to ganciclovir or acy-
clovir, treatment with other antiviral agents (excluding low-
dose acyclovir for prophylaxis of herpes simplex virus), and
exposure to other experimental drugs known to cause marrow
toxicity. The study was approved by the institutional revi~w
boards at the FHCRC, the VAMC, and the COH, and wnt-
ten informed consent was obtained from all patients.
Study medication and dosage schedule
On study day 1 (between 28 and 42 days after transplant),
patients randomly were assigned to a single i.v. (200 rng) or
oral (1000 mg) dose ofganciclovir, and a full serum drug pro-
file was obtained. On day 2, patients received the alternate
route of therapy. Oral ganciclovir therapy was initiated on a 3
times per day dosage schedule on day 3, and 8-hour plasma
drug profiles were obtained from days 6 to 8.
Oral ganciclovir (1000 mg) was administered 3 times per
day from study entry until day 100 after transplantation.
Dosage was adjusted in patients who developed renal
impairment after study entry as follows: CLCR 50-69
ml./mlnute, 1500 mg daily; CLCR 25-49 mlzminute, 1000
mg daily; CLCR 10-24 mUminute, 500 mg daily; CLCR <:10
mLiminute, 500 mg 3 times a week.
Oral ganciclovir was discontinued if CMV viremia or
any level of antigenemia was detected after 7 and 10 days,
respectively, or if marrow toxicity or GI intolerance
occurred after the 3 times per day administration. The dis-
continuation criteria for antigenemia were modified after
two of the first four patients met these criteria but were
deemed to be at low risk for progression of disease. One of
these patients (patient 5) had antigenemia before day 10,
which continued at the same quantitative level after day 10
of oral ganciclovir; the other patient (patient 13) had a
detectable but declining quantitative level of antigenemia
after day 10 of oral ganciclovir, According to the modified
criteria, oral ganciclovir was stopped only if CMV antigene-
mia at a level ;:::2 positive cells per slide with subsequently
increasing levels or antigenemia that was first detected after
10 days of dosing developed. This change was supported by
information that became available showing that subclinical
reactivation of CMV is common in recipients of i.v, ganci-
clovir prophylaxis, i.e., 24% of patients have antigenemia
;:::2 positive cells per slide [7,18J.
Analytical methods
Virological testing. Patients were tested weekly for pp65
antigenemia, for the presence of CMV-DNA in plasma by
PCR, and for CMV excretion from the blood, urine, and
throat by conventional culture and by shell vial centrifugation
(blood only) until day 100 posttransplantation. Heparinized
OralGanciclovir Prophylaxis in CMV Infection
~!o?: 'da; separated by dextran sedimentation, and cells wereCVI e u or culture inoculation and antigenemia testing.
ftve~s IpS of shell vial centrifugation cultures were stained
~ er r20 hours and 40 hours, and tube cultures were held
or at east 3 weeks [19J. For CMV antigenemia testing
cytocentr'fu lid 'bl d 1 I ge s es were prepared using 1.5XI 05 peripheral
st ~o d ~ukocytes. fixed with formaldehyde/NP40, and
sta~n,e Immediately or frozen at -20°C for subsequent
thal~lng. CI0/Cll monoclonal antibodies directed against0; ~ller matrix protein pp65 (Clonab, Biotest Diagnostic,
d nvi e, NJ) and indirect immunofluorescence were used toeteer antigen '[7] F 1aft fil ' enua . or p asma PCR, DNA was extracted
p er. tratlOn of previously frozen plasma using 120 mg/mL
i:ot~lnaseK The mixture was incubated at 55°C for 1 hour,
12~~a~ed at 95°C for 10 minutes, and microcentrifuged at
pl g or 2-5 minutes. PCR was performed using 5 mL of
asma am I'fyig , Ping DNA from the UL83 region of the CMVU~ome (121094-119355) that encodes the pp65 protein.
ot~g ~ompetitivemethod of quantitation, 1-10 copies
und'l genome were routinely detectable in 5 mL ofPer~l uted plasma [20]. Plasma PCR testing mainly wasormed In batches at the COlI.
Gancicl . ,gao . 1 ,ovtr m serum. Serum samples were analyzed for
U .CIC ~Vlr concentrations at the Antiviral Assay Laboratory,
ed~~ehslty of California, San Diego, using a previously report-
19 performance liquid chromatographic method [21].
Pha~macokinetic and statistical analyses
ga .harmacokinetic parameters were determined for oralsta~CI~ovir after single-dose administration and at steady
to~' eak serum ganciclovir concentrations (C
max
) and time
seru max (tm.x> were determined by observation from the
ed m concentration-time curve. The half-life was comput-eli~~ th.e natural logarithm of 2/Kel, with Kel (apparent
sl naoon r~te constant) computed as the magnitude of the
tiope of the Iinear regression of the log concentration vs. the
ml?~ profile during the terminal phase. The steady state
va~nJmum serum concentration level over the dosing inter-
e dCmin,was computed as the mean of the pre-dose and the
cf of the dosing interval concentrations. The total body
to~arance (CL) was computed as the ratio of the i.v, dose to
ti a area under curve (AUC). Apparent volume of distribu-
on at steady state (V
ss
) was computed as follows:
Vss == Dose X (AUMC/AUC2) - T X Dose/2AUC
:here AUMC is the total area under the first moment of the
tierum concentration vs. the time curve and T is the dura-
.on
l
of infusion. The absolute bioavailability (F) of oral gan-CIC '
ovir was calculated from the ratio of AUC(oraI/AUC(i,v.)va~es that were determined after single-dose administration
an Correction for dose.
G'tTTComparison of the pharmacokinetic parameters in
v dO and non-GVHD patients was determined from a one-
Way analysisofvariance. All statistical tests were two-sided and
we adopted a probability level of 0.05 as statisticallysignificant.
Monitoring adverse events
All patients were monitored closely for possible adverse
ev~nts. The modified National Cancer Institute toxicity cri-
tena were used to assess toxicity in this study. Patients did
I1I1&MT
not routinely receive hematopoietic growth factors. Howev-
er, patients who reached the endpoints of neutropenia (i.e,
ANC <750/mm3 for 2 or more consecutive days) could
receive growth factors.
RESULTS
Patients
Of 159 screened CMV seropositive patients, 138 were
not started on oral ganciclovir because of the detection of
CMV infection before day 35 (n=24); renal insufficiency
(n=6); death (n=7); elevated bilirubin (n= 1); nausea, vomit-
ing, or inability to eat before day 42 (n= 15); severe organ
failure or relapse (n=9); refusal (usually because of the num-
ber of capsules, n=35); absence of GI-GVHD (after the
non-GVHD section was closed, n=26); or other reasons
(n= 15). Twenty-one patients received 3 oral doses per day
of oral ganciclovir, seven had and 14 did not have GI-
GVHD. Single-dose pharmacokinetic studies were per-
formed in six of these patients and one additional patient
who did not receive 3 oral doses per day because of the
development of CMV antigenemia. Steady-state pharmaco-
kinetic profiles were performed in 17 patients who had
received at least 5 days of 3 oral doses per day and who
maintained a CLCR >70 mLiminute. One additional patient
was inappropriately enrolled and started on 3 doses per day,
which was discontinued after 6 days because of neutropenia,
nausea, and vomiting. This patient also had GI-GVHD
diagnosed when oral ganciclovir was discontinued, but was
excluded from the analysis because of abnormal renal func-
tion (CLCR 54 mLiminute).
The median duration of oral ganciclovir administration
in 21 patients who were started on three doses per day
(Table 1) was 16 days (range 1-72 days). No difference exist-
ed between patients with or without GI-GVHD (GI-
GVHD, median 16 [range 8-72]; no GI-GVHD, median 15
[range 1-71 days]). .
Pharmacokinetics of oral ganciclovir
The single-dose pharmacokinetics of oral and i.v, ganci-
clovir were determined in CMV-infected patients with
(n=2) or without (n=5) acute GI-GVHD (Table 2). In addi-
tion, the steady-state pharmacokinetics of oral ganciclovir
(1000 mg 3 times per day) were assessed in patients with
(n=6) or without (n= 11) acute GI-GVHD (Table 3).
The presence of acute GI-GVHD did not appear to alter
the GI absorption of orally administered ganciclovir in mar-
row transplant recipients; similar absolute bioavailabilities
were obtained from those with or without acute GI-GVHD
(7.2 vs, 6.9%) (Table 2). Moreover, at steady state the extent
(AUC) and rate (tm.,.) of absorption of oral ganciclovir were
comparable in the two patient subgroups, as reflected in their
similar AUC (13,5 vs. 10.2 mg· hour/L) and tmax (5.5 vs. 3.8
hours) values (Table 3). Patients with acute GVHD tended to
display marginally higher serum ganciclovir concentrations
over the 8-hour dosing interval (Fig. 1).
Antiviral activity of oral gancldovir
Eight of 21 patients developed breakthrough CMV
infection after oral ganciclovir treatment (Table 1). Anti-
genemia at a level 2:2 positive cells per slide occurred in
15
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Table I. Demographic characteristics, virology results, anddiscontinuations ofpatients treated withoralganciclooir 1000mg3 times perday
Donor Other Oral CMV pp65 CMV plasma CMV
Patient status GI-GVHD GVHD ganclclovir" antlgenemlab PCRc cultures d Outcome
-
I MR Yes(21)· No 35-42 35-43 (14) 43 (2066) Urine (35) D/C due to rising antigenemia
2 MUD Yes (12) Skin 31-68, Negative Negative. Negative D/C due to neutropenia
71-80 (ANC 540/mm]) (day 68); DIC due
to nauseaand vomiting (day80)
3 MR Yes(28) No 34-44 43-50 (5) 43-50 (270, 776) Blood (43) D/C due to antlgenemia and
viremia
4 MR Yes (32) Skin 37-91 Negative 57 (2186) Negative Completed .tudy
5 MR Yes(24) Liver 32-47 34-57 (3)' 32-53 (43, 936) Negative DIC due to antlgenemia
6- MUD Yes (27) Skin 32-103 Negative ND Negative Completed study
7 MUD Yes(23) No 38-46 Negative Negative Negative DIC due to nausea and vomiting
8 MR No No 30-57 Negative 48 (1118) Negative DIC due to early discharge from
the center; no adverse events
9 MUD No No 31-46 46 (0.5) Negative Negative DIC due to duodenal perforation
10 MR No No 33-44 Negative Negative Negative DIC due to nausea, vomiting,
and anorexia
II MUD No Skin (15)· 29-91 Negative Negative Negative Completed study
12 MR No Skin, liver (17) 30-100 Negative Negative Negative Completed study
13 MUD No Skin (36) 35-45 38-45 (10) NO Negative DIC due to rising antigenemla
14 MUD No Skin (31) 30-30 Negative NO Negative DIC due to nausea and vomiting;
biopsy-proven GVHD day 33
15~ MUD No No 37-41 NO Negative Blood (41) DIC due to CMV viremia
16~ MUD No No 38-43 NO Negative Negative D/C due to lack of compliance
17 MR No No 42-109 NO Negative Negative Completed study (missed 2 doses
due to nausea and vomiting)
18 MR No Skin (43) 37-87 Negative Negative Negative D/C due to presumed CMV:
pneumonia (not confirmed)
19 MR No Skin (48) 38-68 Negative Negative Negative DIC due to neutropenia
(ANC < 100/mm]) and
abdominal pain
20 MR No Skin (32) 42-55 NO Negative Negative DIC due to thrombocytopenia
(23,000/mml )
21 MUD Ho No 37-45 HI Negative Negative DIC due to nausea and vomiting
-
"Days aftertransplant when oral gancic/ovir wasgiven3 times a day.
bDays aftertransplant withpositive test(maximum number ofantigen-positive cells perslide).
(Days aftertransplant withpositive test(maximum DNA copy number).
dSite ofculture (day aftertransplant).
'Day ofonset ofGVIlD at anysite.
fIn the early phase of thestudy IV,ganciclovir wasstarted when anyantigenemia wasdetected afterday 10 ofdosing.
'No steady-state profile performed because creatinine clearance was<70 mUminute at day 7 ofdosing.
bNo steady-state profile performed because ofearly discontinuation:
ANC, absolute neutrophil count; CMV, cytomegalovirus; DIC, discontinuation; GVIID, greft-us.-bost disease; MRD, matched related donor;
MUD, matched unrelated donor; ND, notdetermined; NI, notinterpretable.
five patients, and all but one (who was not tested) were also
positive as determined by plasma PCR. Two of these
patients were culture-positive (one blood, one urine).
Three additional patients had either low-level antigenemia
«2 positive cells per slide), low DNA copy numbers
«1O,OOO/mL), or viremia by culture (antigenemia was not
tested in this patient). Six of eight patients developed CMV
infection within the first 10 days of treatment; two patients
had breakthrough low-level antigenemia and plasma PCR
positivity after 16 and 21 days, respectively. Patients with
breakthrough antigenemia (see above) or viremia were
treated with i.v, ganciclovir until day 100. Because PCR
results were obtained from frozen specimens, they were not
used to determine the start of i.v, gancicIovir therapy. No
16
CMV disease occurred in any of the patients during the
first 100 days posttransplant,
Tolerability of oral ganclclovlr
Of 21 patients who received prophylaxis with oral gand-
clovir (1000 mg 3 times a day), six (29%) patients had oral
ganciclovir discontinued because of GI adverse events (fable
1). The proportion of patients with GI adverse events leading
to drug discontinuation was similar in patients with or with-
out GI-GVHD (2 of7 vs, 4 of 14). GI events included nausea
and vomiting in five patients and a duodenal perforation in
one patient (Table 1). Whether oral ganciclovir was causally
related to the duodenal perforation remains unclear; a histo-
logic evaluation was not performed. One additional patient
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Table 2. Single-dos ph k" ,f" • .
d e armaco metics oJ mtrauenous ganciclouir (200 mg)an oral gancidovir (1000 g)' C ' , ,e ' m In 'MV-mfected marrow transplant reaps-
mswith orwithout acute GVHD
Table 3. Steady-state pha17l1acokinetics of oralganciclovir (1000 mg) 3
times per day in CMV-infected marrow transplant recipients with or
withoutacute GVHD
c.... (mgll) 7.0 (4.2) 0 8 (t (h .9 (0.5) 6.0 (1.8) O. 0.3)
.... our) 1.0 (0.0) 60 59(3AUC ( . (0.0) 1.1 (0.0) . .6)
Cl (....U mg· h/l) 40.4 (35.4) 13.2 (9.7) 29.2 (14.0) 10.9 (5.2)
m minute) 134 (117) NO /34 (56) NO
V. (l) 50.0 (35.7) NO 50.2 (14.5) ND
t llZ (hour) 6.0 (0.2) 7 6 (I 5) 79 (I I)F(%) .2 (1.3) .0. .•
- 100 7.2 (1.5) 100 6.9 (0.4)
AUC tot I
s 0..", a area under serum concentration-time curve; C"""" peak
terum ~oncentration; CL, totalbody clearance; F, absolute bioavailabi/ity;
st""'d' time to peak serum concentration; v:.s' volume of distribution at
ea!y state' t u ,Re I ' 1/2' e tmmatum half-life; ND, notdetermined.
su tsare presentedasmean :!:: SD.
~~~tient I?) had GI side effects (i.e., abdominal pain) that
o~palUed the discontinuation for neutropenia.
good v~ral1 co~p1ianc~ during drug administration was
total b our patients missed between one and two doses
sient .ecause of GI symptoms. These symptoms were tran-
Conti In ~ree patients and resulted in the permanent dis-
pat' nUatlO.n of oral ganciclovir in only one. Two additional
an I~nts m.Issed doses; one missed one evening dose and
th0 der mIssed three doses because of a failure to obtain<:';50~ug s~pply from the pharmacy. Neutropenia (ANC
rec' mm) occurred in two of 15 patients (13%) who
of ~I~~~oral ganciclovir for more than 10 days (recipients
mat ays n:eatment were used to give a conservative esti-
oceu
e
of the tncidence of neutropenia, which typically
me r~ late during gancidovir treatment) [22]. Dose adjust-
ciclnt . ecause of a reduced CLCR after the start of oral gan-
ando~~ Was required in five patients (for CLCR between 50
mLi ,mLl~inute in two patients and between 25 and 49
sid minUte In three patients). There were no neurologic
Wie Jffects. a.ssociated with oral ganciclovir administration.
tioar I ph~sIclans discontinued oral ganciclovir in two addi-
de~a da~ents (patients 18 and 20) who did not meet pre-
ne diSCOntinuation criteria (Table 1).
Group c.... (mgll) C..ln (mg/l) t .... (h) AUC..~(mg • h/l)
Non·GVHO
(n=/I) 1.6 (0.6) 1.1 (0.6) 3.8 (1.7) 10.2 (4.8)
GVHO
(n=6) 2.2 (0.7) 1.5 (0.5) 5.5 (1.8) 13.5 (4.7)
C",..' trough serum concentration; AUCIJ.~' area under serum concentration-
timecurvefrom0 to8 hours.
Results arepresentedasmeans ::t SD.
Global Development, Palo Alto, CA). Although oral ganci-
dovir has a low absolute bioavailability (6-9%), it undergoes
prolonged absorption from the GI tract, resulting in mean
serum gancidovir concentrations of 0.5-1.0 mg/L in HN-
infected patients [14,15]. The oral bioavailability of ganci-
dovir (-6%) increased in HN-infected patients when the
dosage was accompanied with food [23].
Comparison of these earlier figures with those obtained
in the present study would indicate that the bioavailability
and absorption of oral ganciclovir in allogeneic marrow
transplant recipients is at least as high as those in other
patient groups. The AUCo-oo in marrow transplant patients
after multiple dosing was approximately twice as high as that
in HN-infected individuals (6.1 ::t 3.6 mg . hour/L) [15]
and solid organ transplant recipients (8.2 ::t 2.6 mg .
hour/L) (unpublished data, Roche Global Development).
The absorption rate was similar in both groups. Ganciclovir
clearance seems to be reduced after marrow transplantation
(Table 2) compared with clearance in HN-infected individ-
uals (287 ::t 53 mLiminute) [14]. One could hypothesize
that this phenomenon is because of a marrow transplant
conditioning regimen-related toxicity with renal tubular
damage that is common in marrow transplant recipients
[24]. Ganciclovir is excreted by filtration and tubular secre-
tion [25], and renal tubular damage may be present even
when the CLCR is normal [24]. Thus, the markedly reduced
J.V. Oral
Non-GVHD (n=5)GVHD (n=2)
I.V. OralParameter
-
Figure I. Mean standard deviation serum ganclclovlr profiles at
steady state In CMY-Infected marrow transplant recipients with or
without acute GYHD who received 1000 mg oral ganclclovlr 3
times per day
DISCUSSION
ga ~~is ~tudy demonstrated that the oral bioavailability of
tinnclC ovir is similar to that observed in other patient set-
ad gs, and that acute GVIID of the GI tract does not
OrVtrsely. affect absorption. In addition, discontinuation of
wa ganclclovir because of GI side effects and neutropenia
ti~\common, occurring in sixand two of 21 patients, respec-
of e y.,Subclinical reactivation of CMV occurred in one-third
st patients, most of whom had acute GVHD soon after the
e art of oral ganciclovir treatment, but no case of CMV dis-
gase ,was observed. However, patients were switched to i.v,
anclclovirwhen breakthrough infection occurred.
u Oral gancidovir previously has been reported to display~near p~armacokinetics over a dosage range of 1000-6000
g/day In phase I and II studies (unpublished data, Roche
3
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~
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renal clearance of ganciclovir in marrow transplant recipi-
ents could be a result of a limited excretion of the drug
caused by a subclinical tubular defect.
There was no apparent difference in the absorption
between patients with or without GI-GVHD. Although the
sample of patients was relatively small, this conclusion is
based on single-dose pharmacokinetic profiles (Table 2) and
mean serum levels at steady state (Fig. 1). Patients with the
most severe manifestations of GI-GVHD were often unable
to participate in this study because they could not tolerate the
oral medication. In patients who were able to take the med-
ication, there was no discernible impairment of absorption
compared with patients without GI-GVHD. There is also
the possibility that concomitantly administered medications,
such as eyclosporine or glucocorticosteroids, could affect the
bioavailability of oral ganciclovir. However, the absorption
seen in this study was similar to that observed in other
patient populations [15], making this possibility unlikely.
A potential impediment to the use of any oral medica-
tion soon after marrow transplantation is GI intolerance.
Thirty-one percent of candidates for oral ganciclovir could
not be included in this study because of persistent GI dis-
comfort in the early posttransplant period or patient refusal
of medication, usually because of the number of capsules to
be taken. In addition, six of 21 (29%) patients who were
started on three daily doses of medication had oral ganci-
clovir discontinued because of GI side effects (Table 1). A
ganciclovir pro-drug valganciclovir under development,
which has a higher bioavailability, could reduce the number
of tablets taken, and may perhaps ameliorate both problems.
Neutropenia occurred in two of 15 (13%) patients who
received oral ganciclovir for more than 10 days, a rate lower
than that observed with i.v, ganciclovir (30%) [2,3,7,22]. It is
possible that this lower rate is because of the difference in
peak or trough plasma levels with oral ganciclovir. A study
investigating the correlation between plasma levels and neu-
tropenia is currently underway.
Thirty-eight percent of patients had subclinical reactiva-
tion of CMV while receiving oral ganciclovir (Table 1).
While most of these patients had either antigenemia or PCR
positivity, two patients also had culture-proven viremia.
Although none of these patients progressed to CMV disease,
patients were switched to i.v. ganciclovir when CMV anti-
genemia was detected according to the protocol. We includ-
ed rather strict discontinuation rules for breakthrough infec-
tion because of a concern that patients might progress to dis-
ease. Interestingly, the proportion of patients with subclinical
reactivation in this study appears similar to that reported for
those on i.v, ganciclovir prophylaxis after allogeneic marrow
transplantation (i.e., 41% for antigenemia, 39% for plasma
PCR) [18]. However, follow-up time was shorter in the pres-
ent study. Subclinical reactivation was somewhat more com-
mon in patients with GI-GVHD compared with those with-
out GVHD (four of seven vs, four of 14 patients), which is
consistent with the established role of GVHD as a risk factor
for CMV infection after marrow transplantation.
In conclusion, the bioavailablity of oral ganciclovir in
allogeneic marrow transplant recipients is comparable with
that in other patient populations. However, the AVC
appears higher than that observed in lIN and solid organ
transplant recipients, possibly because of a lower renal clear-
18
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ance, Although the sample of patients is relatively smaIl,
acute GVHD of the GI tract does not seem to adversely
affect absorption. GI intolerance was a limiting factor in t.Ws
setting, probably because of persistent GI toxicity follOWIng'
the conditioning regimens. Thus after marrow transplanta-
tion, oral ganciclovir in its current formulation may best be
tolerated after transplant when GI function is normalized.
i.e., during the maintenance treatment after an initial c~ursf
of i.v, ganciclovir. Initial results on the antiviral actiVlty 0
oral ganciclovir are encouraging. A randomized trial of or~1
ganciclovir for the prevention of CMV infection (pp65 an~­
genemia) is ongoing. Definitive assessment of its val~e In
preventing symptomatic CMV disease, especially in patients
with acute GVHD, requires further study.
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